Pharmaceutical Technology

APRIL 17, 2023

US-based development-stage biopharmaceutical firm Satsuma Pharmaceuticals is developing STS101, a unique nasal powder formulation of the anti-migraine drug dihydroergotamine mesylate, for the treatment of acute migraine. In March 2023, Satsuma submitted a new drug application for STS101 to the US Food and Drug Administration (FDA).

Food and Drug Administration 59

Food and Drug Administration FDA Food Pharmaceutical 59

World of DTC Marketing

MAY 16, 2022

Food and Drug Administration approved Eli Lilly’s novel treatment for diabetes. The drug led to impressive blood sugar and body weight drops in clinical trials. Will patients, who are obese and don’t have Type 2 diabetes, ask for the drug for weight loss, and will patients understand the risks?

Food and Drug Administration 218

Food and Drug Administration Side effects Pharma Prescription 218

Pharmaceutical Technology

APRIL 3, 2023

BioNTech has signed exclusive licence and collaboration agreements with Duality Biologics (DualityBio) for the development of two antibody-drug conjugate (ADC) assets for solid tumours. The agreements also include the manufacturing and commercialisation of the two assets, including DB-1303 and DB-1311, across the globe.

Food and Drug Administration 98

Food and Drug Administration Specialization Food Manufacturing 98

Legacy MEDSearch

MARCH 1, 2024

Boston Scientific’s AGENT Drug-Coated Balloon (DCB) has been granted approval by the U.S. Food and Drug Administration (FDA) for treating coronary in-stent restenosis (ISR) in patients with coronary artery disease. Our clients include both blue-chip companies and innovative startups within the MedTech space.

Food and Drug Administration 52

Food and Drug Administration FDA Recruitment Physicians 52

World of DTC Marketing

JANUARY 10, 2022

It seems that pharma is only interested in drugs that have the potential to sell hundreds of millions as opposed to small products that may only sell to a limited audience. A study in 2020 estimated that the median cost of getting a new drug into the market was $985 million, and the average price was $1.3 5 drugs) ranged from $765.9

Food and Drug Administration 213

Food and Drug Administration Pharma Marketing Food 213

Legacy MEDSearch

MARCH 7, 2024

Food and Drug Administration (FDA) announced the clearance of Dexcom’s device, marking it as the first continuous glucose monitor available over the counter. On March 5, the U.S. Following this announcement, Dexcom’s shares experienced a 2.2% increase in extended trading.

Food and Drug Administration 52

Food and Drug Administration FDA Food Management 52

World of DTC Marketing

SEPTEMBER 7, 2022

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. They relied so much on a new drug that they tried to market a product with bad science behind it. The pharma industry is a giant behemoth that needs new drugs to survive and grow.

Pharma 210

Pharma Food and Drug Administration Marketing Prescription 210

Pharmaceutical Technology

JUNE 20, 2023

The investigational drug candidate vamorolone has a mode of action based on binding to the same receptor as glucocorticoids while changing its downstream activity. In the US and Europe, the drug has received orphan drug status to treat Duchenne muscular dystrophy (DMD).

Food and Drug Administration 98

Food and Drug Administration FDA Prescription Medicine 98

Pharmaceutical Technology

FEBRUARY 14, 2023

Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). upfront payment and eligible for royalties on net sales. CSPC Megalith is a subsidiary of CSPC Pharmaceutical Group.

Food and Drug Administration 52

Food and Drug Administration Pharmaceutical Food FDA 52

Legacy MEDSearch

OCTOBER 25, 2022

EndoStim , a medical device company developing and commercializing a first-in-class implantable neurostimulation treatment for drug refractory gastroesophageal reflux disease (GERD), announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the Company’s EndoStim System.

Food and Drug Administration 98

Food and Drug Administration FDA Side effects Recruitment 98

Legacy MEDSearch

OCTOBER 30, 2023

Medinol today announced United States Food and Drug Administration (FDA) approval for the EluNIR-PERL drug-eluting stent (DES) for the treatment of coronary artery disease. EluNIR-PERL builds upon the proven performance and clinical data of the EluNIR DES system. “We are pleased to bring technologies to the U.S.

Food and Drug Administration 52

Food and Drug Administration FDA Distribution Recruitment 52

Pharmaceutical Technology

MAY 19, 2023

The US Food and Drug Administration (FDA) has approved AbbVie’s Rinvoq (upadacitinib) for patients with Crohn’s disease who do not respond to TNF blockers, a common immune suppressant treatment for the condition.

Food and Drug Administration 105

Food and Drug Administration FDA Sales Food 105

Pharma Leaders

JUNE 28, 2023

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Regeneron Pharmaceuticals for its Biologics License Application (BLA) for aflibercept 8mg to treat wet diabetic macular oedema (DME), age-related macular degeneration (wAMD) and diabetic retinopathy (DR).

Food and Drug Administration 52

Food and Drug Administration FDA Safety Food 52

European Pharmaceutical Review

NOVEMBER 2, 2023

The US Food and Drug Administration ( FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). US sales of Stelara totalled $6.4 He added that the approval of Wezlana “could have a meaningful impact for patients managing their disease.”

Food and Drug Administration 91

Food and Drug Administration FDA Side effects Safety 91

European Pharmaceutical Review

DECEMBER 6, 2022

According to a market report by GlobalData, expanding generic drug competition and a drop in demand for COVID-19 vaccines and therapies have lowered the aggregate market capitalisation of the global top 20 biopharmaceutical companies by 9.1 billion in Q3 from its eye disease drug Eylea. percent from $3.45 trillion in Q2 2022 to $3.14

Biopharma 78

Biopharma Marketing Food and Drug Administration Sales 78

Pharmaceutical Technology

MAY 19, 2023

It received approval from the US Food and Drug Administration in October 2018. EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028. will be paid in equal quarterly instalments in 2024.

Food and Drug Administration 52

Food and Drug Administration Food Pharmaceutical Sales 52

Contrarian Sales Techniques

DECEMBER 14, 2022

The biotechnology and drug sectors performed well in the second half of 2022 after struggling in the first six months. Despite the uncertainty surrounding the global economy, the drug and biotechnology sectors have continued to perform well in the second half of 2022. This can lead to significant losses for large companies.

Food and Drug Administration 52

Food and Drug Administration Pharmaceutical Sales Medicine 52

Pharmaceutical Technology

SEPTEMBER 2, 2022

The rate of drug approvals could be on the rise. In a recent report, GlobalData revealed that the US Food and Drug Administration (FDA) approved 122 new drug applications (NDAs) and biologic license applications (BLAs) in 2021. De-risking drug launch. This figure represents a 2.4% Insourcing vs outsourcing.

Food and Drug Administration 52

Food and Drug Administration Pharma Medicine Distribution 52

Pharmaceutical Technology

MAY 5, 2023

In the US, Eylea’s (aflibercept) net product sales decreased by 6% to $1.43bn from $1.5bn in Q1 2022 owing to a rise in sales-related deductions, partly offset by higher sales volume. Worldwide net sales of Dupixent increased by 37% to $2.49bn Q1 to Q1 2022-23.

Food and Drug Administration 52

Food and Drug Administration Sales Food Pharmaceutical 52

World of DTC Marketing

APRIL 7, 2021

I have to laugh when I hear that a pharma company is patient-centric because that’s become a slogan to make employees feel good about themselves while the costs of prescription drugs increase every year. drug spending by 9 percent” What about taxpayers? Wall Street only cares about one thing; profits and sales outlook.

Healthcare 162

Healthcare Healthcare Food and Drug Administration Pharma 162

Pharmaceutical Technology

JUNE 6, 2023

NRx Pharmaceuticals will receive an initial payment of $10m on obtaining successful findings from the ongoing Phase IIb/III clinical trial and on completion of a Type B meeting with the US Food and Drug Administration (FDA).

Food and Drug Administration 52

Food and Drug Administration Sales FDA Food 52

European Pharmaceutical Review

AUGUST 4, 2023

There are at present, nine US Food and Drug Administration (FDA)-approved agents, GlobalData stated. Worldwide sales for Humira peaked at $21.2 This has developed following numerous adalimumab biosimilar offerings being brought to market. billion in 2022, a product that was launched in 2002.

Marketing 82

Marketing Food and Drug Administration Food Medicine 82

Pharmaceutical Technology

NOVEMBER 11, 2022

For the quarter ending on 30 September 2022, product sales were reported at $10.59bn from $9.7bn in Q3 last year, indicating a growth of 9%. In October, the US Food and Drug Administration (FDA) approved the company’s Imjudo (tremelimumab) plus Imfinzi (durvalumab) for treating adults with unresectable hepatocellular carcinoma.

Food and Drug Administration 96

Food and Drug Administration Food FDA Sales 96

Pharmaceutical Technology

JUNE 19, 2023

The company stated that the collaboration will use the local presence, sales and marketing capabilities of Biomm in Brazil. It plans to seek regulatory approval from the European Medicines Agency, the China National Medical Products Administration and the US Food and Drug Administration.

Food and Drug Administration 52

Food and Drug Administration Distribution Food Marketing 52

Pharmaceutical Technology

JUNE 14, 2023

Novaliq will receive upfront and milestone payments upon achieving regulatory and sales milestones, along with royalties on NOV03 net sales in Japan. Novaliq has also received US Food and Drug Administration approval for VEVYE (cyclosporine ophthalmic solution) 0.1% to treat dry eye disease.

Food and Drug Administration 52

Food and Drug Administration Pharmaceutical Safety Prescription 52

Pharma Leaders

MAY 15, 2023

Filed in the US Bankruptcy Court for the Southern District of Texas, the proceedings will allow the company to pursue expedited sales process. Biopharmaceutical company Athenex and some of its subsidiaries voluntarily have filed Chapter 11 proceedings of the US Bankruptcy Code.

Food and Drug Administration 52

Food and Drug Administration Sales process Food Sales 52

Pharmaceutical Technology

MAY 25, 2023

Celltrion USA has received approval from the US Food and Drug Administration (FDA) for Humira (adalimumab) biosimilar, Yuflyma (adalimumab-aaty) , for multiple indications. It will be offered to patients in prefilled syringe and autoinjector administration options.

Food and Drug Administration 52

Food and Drug Administration FDA Food Safety 52

Pharmaceutical Technology

JULY 13, 2022

Under the deal, the companies will also develop various other drugs that act on cytochrome P450 11A1 (CYP11A1), an enzyme vital for steroid production. Orion will be eligible for milestone payments based on the development and commercialisation of ODM-208 as well as tiered royalty payments on sales contingent on product approval.

Food and Drug Administration 105

Food and Drug Administration Food Marketing Manufacturing 105

Pharmaceutical Technology

MARCH 31, 2023

Brexafemme is claimed to be the only oral antifungal to receive approval from the US Food and Drug Administration (FDA) to treat VVC, as well as reducing RVVC incidence. GSK chief commercial officer Luke Miels said: “The challenge of antimicrobial resistance includes increasing rates of multi-drug resistant fungal infections.

Food and Drug Administration 52

Food and Drug Administration FDA Food Sales 52

Pharmaceutical Technology

APRIL 21, 2023

The remaining $80m component of the deal is based on the achievement of annual sales milestones. Entadfi, a combination of finasteride and tadalafil, is administered as an oral, once-a-day drug to provide a safe and effective treatment option for benign prostatic hyperplasia (BPH), often referred to as enlarged prostate, in men.

Food and Drug Administration 52

Food and Drug Administration Side effects Distribution Food 52

Clarivate

JUNE 23, 2022

As part of our Drugs to Watch series, our team of oncology experts pored over thousands of abstracts for presentations at this year’s just-concluded American Society of Clinical Oncology (ASCO) Annual Meeting. This signifies the growth potential of marketed drugs in established marketplaces and the complexity of oncology treatment paradigms.

Food and Drug Administration 52

Food and Drug Administration Marketing Doctors Patients 52

Pharmaceutical Technology

JANUARY 23, 2023

The China National Medical Products Administration (NMPA) approved fruquintinib for marketing in September 2018. In 2020, fruquintinib received Fast Track designation from the US Food and Drug Administration (FDA) to treat metastatic CRC patients.

Food and Drug Administration 52

Food and Drug Administration Medicine FDA Food 52

Pharmaceutical Technology

APRIL 12, 2023

Under its terms, Pharming has paid a $10m milestone payment to Novartis for the first commercial sale of Joenja. In March 2023, Joenja secured approval from the US Food and Drug Administration (FDA) to treat the targeted patients.

Food and Drug Administration 59

Food and Drug Administration Patients FDA Food 59

Pharmaceutical Technology

MARCH 14, 2023

The agreement is intended for providing commercial support for CTx-1301, after receiving the US Food and Drug Administration (FDA) approval. But the clinical success of a potential treatment can only be realized with commercial excellence, making this partnership between Cingulate and Indegene a critical step for our company. “We

Food and Drug Administration 59

Food and Drug Administration Medical FDA Marketing 59

European Pharmaceutical Review

MAY 2, 2023

Avacincaptad pegol is forecasted to achieve sales of $1.09 Limiting progression of geographic atrophy via C5 inhibition Specifically, ACP, a complement C5 inhibitor, is an investigational drug for GA secondary to AMD and has significant potential to deliver value to a large and underserved patient base, according to Astellas.

Food and Drug Administration 52

Food and Drug Administration Pharma FDA Sales 52

European Pharmaceutical Review

JANUARY 24, 2023

HUTCHMED will receive $400 million upfront as well as up to $730 million on meeting regulatory, development and commercial sales milestones. This is in addition to royalties on net sales. The agreement is valued up to $1.13 billion and strengthens Takeda’s growing oncology portfolio.

Food and Drug Administration 52

Food and Drug Administration Biopharma Medical Sales 52

Pharmaceutical Technology

MAY 10, 2023

The company will also be eligible for additional payments of up to $610m after achieving specified development, regulatory and sales-based milestones, and for tiered royalties on sales. Zion Pharma will receive an upfront payment of $70m, along with near-term milestone payments.

Food and Drug Administration 52

Food and Drug Administration Food Pharma Sales 52